Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. More Details
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Madrigal Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MDGL has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: MDGL exceeded the US Biotechs industry which returned 25% over the past year.
Return vs Market: MDGL exceeded the US Market which returned 12% over the past year.
Price Volatility Vs. Market
How volatile is Madrigal Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StMadrigal Pharmaceuticals (NASDAQ:MDGL) Is In A Good Position To Deliver On Growth Plans
4 months ago | Simply Wall StDoes The Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Share Price Tend To Follow The Market?
1 year ago | Simply Wall StRead This Before Selling Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares
Is Madrigal Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MDGL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MDGL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MDGL is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: MDGL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MDGL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MDGL is overvalued based on its PB Ratio (5.8x) compared to the US Biotechs industry average (3.3x).
How is Madrigal Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDGL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MDGL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MDGL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if MDGL's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if MDGL's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MDGL is forecast to be unprofitable in 3 years.
How has Madrigal Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MDGL is currently unprofitable.
Growing Profit Margin: MDGL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MDGL is unprofitable, and losses have increased over the past 5 years at a rate of 48.1% per year.
Accelerating Growth: Unable to compare MDGL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDGL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.8%).
Return on Equity
High ROE: MDGL has a negative Return on Equity (-39.17%), as it is currently unprofitable.
How is Madrigal Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: MDGL's short term assets ($386.6M) exceed its short term liabilities ($45.3M).
Long Term Liabilities: MDGL's short term assets ($386.6M) exceed its long term liabilities ($197.0K).
Debt to Equity History and Analysis
Debt Level: MDGL is debt free.
Reducing Debt: MDGL currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MDGL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: MDGL has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 42% each year.
What is Madrigal Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MDGL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MDGL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MDGL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MDGL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MDGL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Paul Friedman (77 yo)
Dr. Paul A. Friedman, M.D., has been Chairman of the Board at Prelude Therapeutics Incorporated and has been its Director since July 2016. He has been Chairman and Chief Executive Officer of Madrigal Pharm ...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD6.09M) is above average for companies of similar size in the US market ($USD4.53M).
Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.
|Chairman & CEO||4.25yrs||US$6.09m||5.22% |
|Senior VP & CFO||4.25yrs||US$3.53m||0.27% |
|Senior VP & General Counsel||1.58yrs||US$4.12m||0.0032% |
|Senior Vice President of Clinical Management||no data||no data||no data|
|Senior VP & Chief Commercial Officer||0.50yr||no data||no data|
Experienced Management: MDGL's management team is considered experienced (2.9 years average tenure).
|Chairman & CEO||4.25yrs||US$6.09m||5.22% |
|Independent Director||4.25yrs||US$657.50k||0% |
|Independent Lead Director||4.25yrs||US$657.50k||2.98% |
|Independent Director||4.25yrs||US$670.00k||0% |
|Independent Director||4.25yrs||US$662.50k||0.11% |
|Independent Director||4.17yrs||US$663.25k||0.059% |
|Independent Director||1.33yrs||US$1.31m||0% |
Experienced Board: MDGL's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Madrigal Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Madrigal Pharmaceuticals, Inc.
- Ticker: MDGL
- Exchange: NasdaqGS
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.981b
- Shares outstanding: 15.44m
- Website: https://www.madrigalpharma.com
Number of Employees
- Madrigal Pharmaceuticals, Inc.
- Four Tower Bridge
- Suite 400
- West Conshohocken
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MDGL||NasdaqGS (Nasdaq Global Select)||Yes||New Common Stock||US||USD||Jul 2016|
|YDO1||DB (Deutsche Boerse AG)||Yes||New Common Stock||DE||EUR||Jul 2016|
|0JXI||LSE (London Stock Exchange)||Yes||New Common Stock||GB||USD||Jul 2016|
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and li ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/30 04:27|
|End of Day Share Price||2020/10/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.